BAP1 (BRCA1 Associated Protein 1) Drug Discovery Landscape & Assay Solutions
- By admin
- 08 May 2026
- Comments
Subtitle: Deubiquitinase Target Validation, Synthetic Lethality Screening, and Chromatin Regulator Research Tools
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BAP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | BAP1 Full-Length & Catalytic Domain Recombinant Protein Sequence Verified, High Purity (>95%), Endotoxin <1EU/μg. HEK293 Expressed. |
View BAP1 Products |
| Antigen (Mutant) | BAP1 Mutant Panel (C91A, Q684*, W439*) Catalytically inactive & Cancer-derived truncations for mechanism studies. |
View BAP1 Products |
| Gene Delivery | BAP1 Lentivirus Particles (WT & Mutants) For stable isogenic cell line construction in synthetic lethality assays. |
View BAP1 Products |
| Benchmark Ab | Anti-BAP1 Monoclonal Antibody High specificity for Western Blot and IHC validation. |
View BAP1 Products |
| Validator | BAP1 siRNA / shRNA Plasmids For knockdown and specificity controls in functional assays. |
View BAP1 Products |
| EZH2 | Enhancer of Zeste Homolog 2 Synthetic lethality partner with BAP1 loss; essential for compensatory screening. |
View EZH2 Products |
| ASXL1 | Additional Sex Combs Like 1 Required cofactor for BAP1 DUB activity; complex formation assays. |
View ASXL1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DUB Catalytic Activity Validation | Active Site Cysteine Verified; C91A Mutant available as negative control; High purity (>95%) for kinetic assays. |
| Synthetic Lethality Isogenic Models | Matched WT and Loss-of-function (Q684*, W439*) Lentivirus pairs for CRISPR-complementary studies. |
| Complex Formation (ASXL1/2) | Full-length BAP1 with native folding; Endotoxin controlled for sensitive cell-based interaction assays. |
| Specificity Controls | Validated siRNA sets included for target engagement confirmation. |
Live BAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic focus on BAP1 has shifted from direct inhibition (given its tumor suppressor role) to exploiting synthetic lethality in BAP1-deficient malignancies. With 50-70% of mesotheliomas and 80% of metastatic uveal melanomas harboring BAP1 mutations, the current R&D wave targets compensatory pathways such as EZH2, PRMT5, and HDAC complexes. As first-generation EZH2 inhibitors advance, the demand for high-fidelity BAP1 mutant isogenic models and catalytically validated DUB assays has intensified to differentiate on-target from off-target effects in chromatin regulation studies.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Synthetic Lethality (EZH2i) | Ideaya Biosciences, GSK, Novartis | Malignant Mesothelioma, Uveal Melanoma | Isogenic WT vs Mutant Cell Lines (Lentivirus-based) |
| DUB Inhibitor (Mechanism) | Academic Consortia, Forma Therapeutics | Myeloid Malignancies | Catalytic Domain + C91A Mutant Pair for Specificity |
| Diagnostic IHC | Roche, Agilent | Renal Cell Carcinoma, Melanoma | High-specificity Benchmark Antibodies |
| PROTAC (Complex Targeting) | Emerging Biotech | Solid Tumors | Full-length BAP1-ASXL1 Complex Proteins |